Interestingly, TUSC3 loss alters ER stress to facilitate prostate cancer progression (29), and recent data evidence that TUSC3-deficiency enhances ATF6-mediated UPR and metastatic potential to aggravate cancer development in non-small cell lung cancer (16), but the detailed mechanisms have not been fully delineated. This evidence concerns the gene ATF6 and prostate cancer.